# MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)

Study · id `cardio:ct-nct06128629` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06128629](<https://clinicaltrials.gov/study/NCT06128629>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT06128629

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1200 participants.

## Technical summary

Registry record NCT06128629. Randomized; quadruple masking; primary purpose treatment. Start 2023-12-13 (actual); primary completion 2027-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1200 participants (planned count; ClinicalTrials.gov record NCT06128629, source copy `cardio:ctgov-nct06128629-2026-11-04`, retrieved 2026-11-18)
- Started: 2023-12-13 (actual) (ClinicalTrials.gov record NCT06128629, source copy `cardio:ctgov-nct06128629-2026-11-04`, retrieved 2026-11-18)
- Primary completion: 2027-12 (anticipated) (ClinicalTrials.gov record NCT06128629, source copy `cardio:ctgov-nct06128629-2026-11-04`, retrieved 2026-11-18)
- Completion: 2028-04 (anticipated) (ClinicalTrials.gov record NCT06128629, source copy `cardio:ctgov-nct06128629-2026-11-04`, retrieved 2026-11-18)
- Countries: United States; Argentina; Australia; Austria; Belgium; Brazil; Canada; Czechia; Denmark; France; Germany; Hungary; Israel; Italy; Japan; Mexico; Netherlands; New Zealand; Norway; Portugal; Singapore; South Korea; Spain; Sweden; Taiwan; United Kingdom (ClinicalTrials.gov record NCT06128629, source copy `cardio:ctgov-nct06128629-2026-11-04`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06128629-2026-11-04`, retrieved 2026-11-18)

## The registry's words

- Brief title: MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
- Condition: Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
- Intervention (Biological): NTLA-2001
- Intervention (Drug): Placebo
- Lead sponsor: Intellia Therapeutics
- Lead sponsor class: INDUSTRY
- Collaborator: Regeneron Pharmaceuticals
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Cardiac amyloidosis (`cardio:cardiac-amyloidosis`)
- Registry condition terms include this condition: Cardiomyopathy (heart muscle disease) (`cardio:cardiomyopathy`)
- Registry lists this organization as a collaborator: Regeneron Pharmaceuticals (`cardio:org-regeneron-pharmaceuticals`)

## Provenance

Content hash: 9f5a46335ac2e6b7fdead7284146b3de516864d24116d0c19cedc0a56649ff96
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
